Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics

Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics

Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Micro...

Full description

Saved in:

Bibliographic Details
Main Author:	Jinwei Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Marine Drugs
Subjects:	marine-derived compounds cancer therapy renal disease autophagy metabolic-associated fatty liver disease immune checkpoint inhibitors
Online Access:	https://www.mdpi.com/1660-3397/23/7/283
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Marine-Derived Bioactive Ingredients in Functional Foods for Aging: Nutritional and Therapeutic Perspectives
by: Youngji Han, et al.
Published: (2024-11-01)

Marine-Derived Antioxidants: A Comprehensive Review of Their Therapeutic Potential in Oxidative Stress-Associated Diseases
by: Ruiqiu Zhang, et al.
Published: (2025-05-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01)

Marine-Derived Bioactive Compounds: A Promising Strategy for Ameliorating Skeletal Muscle Dysfunction in COPD
by: Meiling Jiang, et al.
Published: (2025-04-01)

Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature
by: Nishika Karbhari, et al.
Published: (2024-11-01)

Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease
by: Min Tang, et al.
Published: (2020-01-01)

Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease
by: Suwei Jin, et al.
Published: (2025-01-01)

Therapeutic Potential of Plant- and Marine-Derived Bioactive Compounds in Prostate Cancer: Mechanistic Insights and Translational Applications
by: Arif Jamal Siddiqui, et al.
Published: (2025-02-01)

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease
by: Daniela Ciobârcă, et al.
Published: (2025-02-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Targeting Ferroptosis in Tumors: Novel Marine-Derived Compounds as Regulators of Lipid Peroxidation and GPX4 Signaling
by: Yimao Wu, et al.
Published: (2025-06-01)

Vitamin D Attenuates Hepatic Sinusoidal Capillarization in Type 2 Diabetes Mellitus– Metabolic Dysfunction-Associated Fatty Liver Disease via Dual Autophagy Activation and Pyroptosis Suppression in Liver Sinusoidal Endothelial Cells
by: Panpan Jiang, et al.
Published: (2025-06-01)

Recovery of Lysosomal Acidification and Autophagy Flux by Attapulgite Nanorods: Therapeutic Potential for Lysosomal Disorders
by: Yuanjing Hao, et al.
Published: (2025-05-01)

Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector
by: Laura M. Teixeira, et al.
Published: (2025-05-01)

Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality
by: Mahsa Abbaszadeh, et al.
Published: (2025-05-01)

Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus
by: Yu-Ming Cheng, et al.
Published: (2024-09-01)

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
by: Yue Wang, et al.
Published: (2025-02-01)

Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025
by: Jennifer Panganiban, et al.
Published: (2025-06-01)

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
by: Xianhua Mao, et al.
Published: (2025-07-01)

New Pyridinium Compound from Marine Sediment-Derived Bacterium <i>Bacillus licheniformis</i> S-1
by: Han Wang, et al.
Published: (2024-12-01)

Liver fibrosis progression analyzed with AI predicts renal decline
by: Dan-Qin Sun, et al.
Published: (2025-05-01)

Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)
by: Alexander A. Baranov, et al.
Published: (2025-05-01)

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis
by: Farah Abdelhameed, et al.
Published: (2025-04-01)

The pro-fibrotic role of autophagy in renal intrinsic cells: mechanisms and therapeutic potential in chronic kidney disease
by: Ying-Ying Zhang, et al.
Published: (2024-12-01)

Marine-Derived Polysaccharides and Their Potential Health Benefits in Nutraceutical Applications
by: Joana Carrasqueira, et al.
Published: (2025-01-01)

Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease
by: Wandi Li, et al.
Published: (2024-12-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma
by: Yiming Jin, et al.
Published: (2025-08-01)

Physical activity as a multitarget therapy for metabolically associated fatty liver disease
by: E. A. Lyalyukova, et al.
Published: (2022-02-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
by: Rachmad Anres Dongoran, et al.
Published: (2023-01-01)

Exploring marine-derived bacterial compounds targeting the μ-opioid receptor agonists through metabolic profiling to molecular modeling
by: Daouia Boudrahem, et al.
Published: (2025-05-01)

Is nonalcoholic fatty liver disease associated with metabolic syndrome? An experience from a medical college of West Bengal, India
by: Sounak Sinha, et al.
Published: (2025-06-01)

An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease
by: Qicong Li, et al.
Published: (2025-08-01)

Models incorporating physical, laboratory and gut metabolite markers can be used to predict severe hepatic steatosis in MAFLD patients
by: Yi‐Hsuan Lin, et al.
Published: (2024-12-01)

In Vitro and In Silico Studies on the Anti-H1N1 Activity of Bioactive Compounds from Marine-Derived <i>Streptomyces ardesiacus</i>
by: Yung-Husan Chen, et al.
Published: (2025-03-01)

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
by: Woo-Young Shin, et al.
Published: (2025-04-01)

Associations of Metabolic Dysfunction–Associated Fatty Liver Disease With Peripheral Artery Disease: Prospective Analysis in the UK Biobank and ARIC Study
by: YueRuiJing Liu, et al.
Published: (2024-11-01)

Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study
by: Yasutaka Takeda, et al.
Published: (2025-05-01)

Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives
by: Chunyan Chen, et al.
Published: (2025-04-01)